Telavancin

DEA Class; Rx

Common Brand Names; Vibativ

Indicated for skin and skin structure infections caused by Gram-positive bacteria including Staphylococcus aureus (including methicillin-resistant and methicillin-susceptible strains), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus group (includes S anginosus, S intermedius, and S constellatus), and Enterococcus faecalis (vancomycin-susceptible isolates only)

Indicated for hospital-acquired, including ventilator-associated bacterial pneumonia caused by susceptible isolates of Staphylococcus aureus (including methacillin-relesistant and vancomycin-intermediate strains) when alternative treatments are not suitable

Hypersensitivity

Use of intravenous unfractionated heparin sodium

New onset or worsening renal impairment has been reported (monitor renal function)

Efficacy decreased with moderate-to-severe baseline renal impairment (ie, CrCl <50 mL/min) for skin and skin structure infections

Administer over at least 1 hr to minimize infusion-related adverse reactions

Clostridium difficile-associated diarrhea may occur

May prolong QTc interval; coadministration with other drugs that prolong QTc interval (eg, phenothiazine, TCAs, macrolide antibiotics, class I and III antiarrhythmic agents) increased risk for life-threatening arrhythmias

Interferes with coagulation tests including PT, INR, and APT, but does not interfere with coagulation

There is a pregnancy registry that monitors pregnancy outcomes in women exposed to therapy during pregnancy

There are no data on presence of telavancin in human milk, effects on breastfed child, or on milk production

Telavancin

injection, lyophylized powder

• 750mg/vial